2-(9H-purin-9-yl)acetic acid | 98550-24-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(9H-purin-9-yl)acetic acid
• 英文别名: (9H-Purin-9-yl)-essigsaeure；Purin-9H-essigsaeure；purin-9-yl-acetic acid；2-purin-9-ylacetic acid
• CAS: 98550-24-4
• 化学式: C₇H₆N₄O₂
• 分子量: 178.15
• InChiKey: PPVLXVYICMYPNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  80.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3as,4r,5s,6s,8r,9r,9ar,10r)-5-Hydroxy-4,6,9,10-Tetramethyl-1-Oxo-6-Vinyldecahydro-3a,9-Propanocyclopenta[8]annulen-8-Yl (Piperidin-4-Ylthio)acetate 、 2-(9H-purin-9-yl)acetic acid 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Pleuromutilin derivatives having a purine ring. Part 1: New compounds with promising antibacterial activity against resistant Gram-positive pathogens

  摘要：

  In the course of our research aimed at the discovery of metabolic stable pleuromutilin derivatives with more potent antibacterial activity against Gram-positive pathogens than previous analogues, a series of compounds bearing a purine ring were prepared and evaluated. From SAR studies, we identified two promising compounds 85 and 87, which have excellent in vitro activity against a number of Gram-positive pathogens, including existing drug-resistant strains, and potent in vivo efficacy. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.011
• 作为产物：
  描述：

  2-嘌呤-9-乙酸乙酯 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 以55%的产率得到2-(9H-purin-9-yl)acetic acid
  参考文献：
  名称：

  以嘌呤碱为P2-配体的新型HIV-1蛋白酶抑制剂的合成和生物学评估。

  摘要：

  将嘌呤碱基引入P2-配体可能会增强人类免疫缺陷病毒1（HIV-1）蛋白酶抑制的效力，因为羰基和NH基团促进了广泛的H键相互作用的形成。在这项工作中，合成和评估了33种化合物，其中含有N-2-（6-取代的9H-嘌呤-9-基）乙酰胺作为P2-配体以及4-甲氧基苯基磺酰胺的抑制剂16a，16f和16j作为P2'-配体，分别在体外对IC50的IC50浓度为43 nM，42 nM和68 nM表现出有效的抑制作用。

  DOI：

  10.1016/j.bmcl.2019.03.049

文献信息

• SUBSTITUTED 2-(9H-PURIN-9-YL) ACETIC ACID ANALOGUES AS INHIBITORS OF STAT3
  申请人：Turkson James

  公开号：US20130172340A1

  公开（公告）日：2013-07-04

  In one aspect, the invention relates to substituted purine analogs, derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在某个方面，本发明涉及取代嘌呤类似物、其衍生物和相关化合物，这些化合物可用作STAT蛋白活性的抑制剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与STAT蛋白活性功能障碍相关的细胞无控制增殖疾病的方法。本摘要旨在作为搜索特定技术领域的扫描工具，不旨在限制本发明。
• Metal-free direct C-6–H alkylation of purines and purine nucleosides enabled by oxidative homolysis of 4-alkyl-1,4-dihydropyridines at room temperature
  作者：Qingsong Jiang、Xiguang Liu、Weili Wang、Yiwen Chen、Mingwu Yu

  DOI：10.1039/d2ob02070j

  日期：——

  Herein we report the application of 4-alkyl-1,4-dihydropyridines (DHPs), which are easily prepared from inexpensive aldehydes in one step, for the direct site-specific C–H alkylation of purines and purine nucleosides. Despite there being three active C(sp2)–H bonds (C-2–H, C-6–H, and C-8–H) in the structure, the reactions still show high regioselectivity at the purinyl C-6–H position. Importantly,

  在这里，我们报告了 4-烷基-1,4-二氢吡啶 (DHP) 的应用，它很容易从廉价的醛一步制备，用于嘌呤和嘌呤核苷的直接位点特异性 C-H 烷基化。尽管结构中存在三个活性 C(sp 2 )–H 键（C-2–H、C-6–H 和 C-8–H），但反应在嘌呤基 C-6– 处仍显示出高区域选择性H位置。重要的是，该反应成功地避免了使用过渡金属催化剂和额外的酸。同时，这些协议对水分不敏感，只需要过硫酸盐作为氧化剂。此外，该方法具有广泛的功能组兼容性，易于放大。值得注意的是，药用嘌呤，例如从担子菌中分离出的天然产物 6-hydroxymethyl nebularine 可以使用该协议顺利制备。
• METHODS AND COMPOSITIONS FOR TARGETING TUMOR MICROENVIRONMENT AND FOR PREVENTING METASTASIS
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3049110A2

  公开（公告）日：2016-08-03
• REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS
  申请人：Sienna Biopharmaceuticals, Inc.

  公开号：EP3600440A1

  公开（公告）日：2020-02-05
• COMPOSITIONS AND METHODS FOR INIHIBITING TUMORIGENICITY OF SENESCENT CANCER CELLS INDUCED BY CHEMOTHERAPY
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：US20150056195A1

  公开（公告）日：2015-02-26

  The invention relates to the field of oncology and to chemotherapy resistance and relapse. Thus the invention provides compositions and methods for inhibiting tumorigenicity of senescent cancer cells induced by a chemotherapeutic agent. The invention also provides compositions and methods for inhibiting conversion of non-stem cancer cells (non-CSCs) into tumor initiating cancer stem cells (CSCs) induced by a chemotherapeutic agent.